Expert Review of Anticancer Therapy最新文献_第3页

Liquid biopsies for detection, surveillance, and prognosis of urothelial cancer: a future standard? 癌症尿路上皮检测、监测和预后的液体活检：未来的标准？

IF 3.3 3区医学

Expert Review of Anticancer Therapy Pub Date : 2023-07-01 Epub Date: 2023-08-08 DOI: 10.1080/14737140.2023.2245144

Igor Duquesne, Mohamad Abou Chakra, Lory Hage, Ugo Pinar, Yohann Loriot

{"title":"Liquid biopsies for detection, surveillance, and prognosis of urothelial cancer: a future standard?","authors":"Igor Duquesne, Mohamad Abou Chakra, Lory Hage, Ugo Pinar, Yohann Loriot","doi":"10.1080/14737140.2023.2245144","DOIUrl":"10.1080/14737140.2023.2245144","url":null,"abstract":"Introduction: Liquid biopsies are used for the detection of tumor-specific elements in body fluid. Their application in prognosis and diagnosis of muscle/non-muscle invasive bladder cancer (MIBC/NMIBC) or upper tract urothelial cancer (UTUC) remains poorly known and rarely mentioned in clinical guidelines.Areas covered: Herein, we provide an overview of current data regarding the use of liquid biopsies in urothelial tumors.Expert opinion: Studies that were included analyzed liquid biopsies using the detection of circulating tumor cells (CTCs), deoxyribonucleic acid (DNA), ribonucleic acid (RNA), exosomes, or metabolomics. The sensitivity of blood CTC detection in patients with localized cancer was 35% and raised to 50% in patients with metastatic cancer. In NMIBC patients, blood CTC was associated with poor prognosis, whereas discrepancies were seen in MIBC patients. Circulating plasma DNA presented a superior sensitivity to urine and was a good indicator for diagnosis, follow-up, and oncological outcome. In urine, specific bladder cancer (BC) microRNA had an overall sensitivity of 85% and a specificity of 86% in the diagnosis of urothelial cancer. These results are in favor of the use of liquid biopsies as biomarkers for in urothelial cancer management.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":"23 9","pages":"995-1007"},"PeriodicalIF":3.3,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10294271","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Efficacy and safety of CalliSpheres® microspheres drug-eluting beads transarterial chemoembolization in GCLM combined trans-arterial infusion therapy for treating primary focus of gastric cancer: a multi-center retrospective study. CalliSpheres®微球药物洗脱珠经动脉化疗栓塞术在GCLM联合经动脉灌注治疗癌症原发灶中的有效性和安全性：一项多中心回顾性研究。

IF 3.3 3区医学

Expert Review of Anticancer Therapy Pub Date : 2023-07-01 Epub Date: 2023-07-28 DOI: 10.1080/14737140.2023.2239496

Guang Sheng Zhao, Jin Bo Sun, Song Liu, Fang Xu, Jian Ma, Chuang Li, Fei Gao, Jun Zhou, Ruo Yu Wang, Song Nian Liang

{"title":"Efficacy and safety of CalliSpheres® microspheres drug-eluting beads transarterial chemoembolization in GCLM combined trans-arterial infusion therapy for treating primary focus of gastric cancer: a multi-center retrospective study.","authors":"Guang Sheng Zhao, Jin Bo Sun, Song Liu, Fang Xu, Jian Ma, Chuang Li, Fei Gao, Jun Zhou, Ruo Yu Wang, Song Nian Liang","doi":"10.1080/14737140.2023.2239496","DOIUrl":"10.1080/14737140.2023.2239496","url":null,"abstract":"Background: The purpose of this study was to observe the safety and efficacy of CalliSpheres microspheres drug-eluting beads (DEB) transhepatic arterial chemoembolization (CSM-TACE) for liver metastasis of gastric cancer (GCLM) combined with trans-arterial infusion therapy (TAIT) as the primary focus of gastric cancer.Research design and methods: Unresectable advanced GCLM patients were collected for retrospective analysis. Patients who progressed after chemotherapy or could not receive systematic chemotherapy were selected. CSM-TACE was used for GCLM treatment and oxaliplatin for TAIT of primary focus of gastric cancer. Adverse reactions, tumor reactions, survival rate, and survival time during treatment were recorded, and prognostic factors were analyzed.Results: Forty-three patients from four oncology centers met inclusion criteria and were enrolled. CSM-TACE averaged (1.51 ± 0.51) times and TAIT averaged (4.58 ± 1.65) times. The follow-up time was 2.5-49 months, and the 6-month, 1-year, and 2-year survival rates were 86.0%, 72.1%, and 41.9%, respectively, with a median overall survival of 11.5 months. The adverse reactions during treatment were grade 1-3. The hazard ratio (HR) of combination therapy was 0.51 (P = 0.040), and the HR of TAIT frequency was 0.34 (P = 0.002), which were independent protective factors affecting prognosis.Conclusions: CSM-TAC for GCLM combined with TAIT for primary focus of gastric cancer is safe and efficacious, which is worthy of clinical promotion and application.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":"23 9","pages":"1009-1016"},"PeriodicalIF":3.3,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10301429","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Oral therapy for myelodysplastic syndromes/neoplasms and acute myeloid leukemia: a revolution in progress. 骨髓增生异常综合征/肿瘤和急性髓系白血病的口服治疗：一场正在进行的革命。

IF 3.3 3区医学

Expert Review of Anticancer Therapy Pub Date : 2023-07-01 Epub Date: 2023-07-20 DOI: 10.1080/14737140.2023.2238897

Sangeetha Venugopal, Rory M Shallis, Amer M Zeidan

{"title":"Oral therapy for myelodysplastic syndromes/neoplasms and acute myeloid leukemia: a revolution in progress.","authors":"Sangeetha Venugopal, Rory M Shallis, Amer M Zeidan","doi":"10.1080/14737140.2023.2238897","DOIUrl":"10.1080/14737140.2023.2238897","url":null,"abstract":"Introduction: Patients with myeloid neoplasms such as myelodysplastic syndromes/neoplasms (MDS) and acute myeloid leukemia (AML) are generally older, and many are not eligible for curative intent intensive therapies and/or allogeneic hematopoietic stem cell transplantation. While lower intensity, hypomethylating agent (HMA)-based therapies such as azacitidine+venetoclax have improved patient outcomes significantly, responses are not durable, and most patients die from disease-related complications. The approvals of oral HMAs such as cedazuridine-decitabine (C-DEC) and oral azacitidine (CC-486) have kindled the hope that myeloid malignancies may soon be treated with total oral therapy.Areas covered: We review all-oral therapies including the approvals of C-DEC and CC-486 in MDS and AML, respectively, in addition to emerging all-oral therapies, both monotherapy and combination, in higher-risk (HR) MDS and AML.Expert opinion: Oral HMAs have the potential to be a convenient and efficacy-equivalent treatment option for patients with HR-MDS or AML and improve their quality of life by reducing clinic visits for medication administration. Total-oral therapy combinations, largely including an oral HMA 'backbone,' are in the early phases of clinical development, and it is our hope that well-designed trials employing these agents may soon allow the identification of optimal regimens that deliver effective disease-directed therapy with good tolerability.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":"23 9","pages":"903-911"},"PeriodicalIF":3.3,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10302769","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pediatric cancer care management during the COVID-19 pandemic: a review of the literature and a single-centre real-life experience of an Italian pediatric oncology unit. 新冠肺炎大流行期间的癌症儿科护理管理：文献综述和意大利儿科肿瘤科的单中心真实体验。

IF 3.3 3区医学

Expert Review of Anticancer Therapy Pub Date : 2023-07-01 Epub Date: 2023-09-15 DOI: 10.1080/14737140.2023.2245148

Olga Nigro, Chiara Oltolini, Federica Barzaghi, Caterina Uberti Foppa, Maria Pia Cicalese, Maura Massimino, Elisabetta Schiavello

{"title":"Pediatric cancer care management during the COVID-19 pandemic: a review of the literature and a single-centre real-life experience of an Italian pediatric oncology unit.","authors":"Olga Nigro, Chiara Oltolini, Federica Barzaghi, Caterina Uberti Foppa, Maria Pia Cicalese, Maura Massimino, Elisabetta Schiavello","doi":"10.1080/14737140.2023.2245148","DOIUrl":"10.1080/14737140.2023.2245148","url":null,"abstract":"Introduction: The severe acute respiratory syndrome coronavirus-2 pandemic significantly affected clinical practice, also in pediatric oncology units. Cancer patients needed to be treated with an adequate dose density despite the SARS-CoV-2 infection, balancing risks of developing severe COVID-19 disease.Areas covered: Although the pandemic spread worldwide, the prevalence of affected children was low. The percentage of children with severe illness was approximately 1-6%. Pediatric cancer patients represent a prototype of a previously healthy immune system that is hampered by the tumor itself and treatments, such as chemotherapy and steroids. Through a review of the literature, we reported the immunological basis of the response to SARS-CoV-2 infection, the existing antiviral treatments used in pediatric cancer patients, and the importance of vaccination. In conclusion, we reported the real-life experience of our pediatric oncology unit during the pandemic period.Expert opinion: Starting from the data available in literature, and our experience, showing the rarity of severe COVID-19 disease in pediatric patients with solid tumors, we recommend carefully tailoring all the oncological treatments (chemotherapy/targeted therapy/stem cell transplantation/radiotherapy). The aim is the preservation of the treatment's timing, balanced with an evaluation of possible severe COVID-19 disease.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":"23 9","pages":"927-942"},"PeriodicalIF":3.3,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10307021","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Lutetium-177 PSMA for the treatment of metastatic castrate resistant prostate cancer: a systematic review. 用于治疗转移性阉割抵抗性前列腺癌的镥-177 PSMA：系统综述。

IF 3.3 3区医学

Expert Review of Anticancer Therapy Pub Date : 2023-07-01 Epub Date: 2023-05-24 DOI: 10.1080/14737140.2023.2213892

Kanchi Patell, Matthew Kurian, Jorge A Garcia, Prateek Mendiratta, Pedro C Barata, Angela Y Jia, Daniel E Spratt, Jason R Brown

{"title":"Lutetium-177 PSMA for the treatment of metastatic castrate resistant prostate cancer: a systematic review.","authors":"Kanchi Patell, Matthew Kurian, Jorge A Garcia, Prateek Mendiratta, Pedro C Barata, Angela Y Jia, Daniel E Spratt, Jason R Brown","doi":"10.1080/14737140.2023.2213892","DOIUrl":"10.1080/14737140.2023.2213892","url":null,"abstract":"Introduction: Metastatic castrate resistant prostate cancer (mCPRC) remains an aggressive form of prostate cancer that no longer responds to traditional hormonal treatment alone. Despite the advent of novel anti-androgen medications, many patients continue to progress, and as a result, there is a growing need for additional treatment options.Areas covered: Lutetium-177 (177Lu) - PSMA-617 has become one of the new frontline treatment options for refractory metastatic castrate resistant prostate cancer after the failure of novel anti-androgen therapy and chemotherapy. Lu-177 has been used in real-world prospective trials and is now becoming utilized in newer phase III clinical trials. Here, we present a comprehensive overview of the current literature, covering retrospective studies, prospective studies, and clinical trials that established Lutetium-177-PSMA-617 (177Lu-PSMA-617) for the treatment of mCRPC.Expert opinion: 177Lu - PSMA-617 has been approved for treatment of mCRPC based on positive phase III studies. While this treatment is tolerable and effective, biomarkers are necessary to determine which patients will benefit. In the future, radioligand treatments will likely be utilized in earlier lines of therapy and potentially in combination with other prostate cancer treatments.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":"23 7","pages":"731-744"},"PeriodicalIF":3.3,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9650628","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

How can we refine the prognostic stratification of triple-negative breast cancer? 如何完善癌症三阴性的预后分层？

IF 3.3 3区医学

Expert Review of Anticancer Therapy Pub Date : 2023-07-01 Epub Date: 2023-08-17 DOI: 10.1080/14737140.2023.2248387

Federica Miglietta, Maria Vittoria Dieci

引用次数: 0

Mirvetuximab soravtansine for platinum-resistant epithelial ovarian cancer. Mirvetuximab soravtansine治疗卵巢上皮性癌症铂耐药性。

IF 3.3 3区医学

Expert Review of Anticancer Therapy Pub Date : 2023-07-01 Epub Date: 2023-07-24 DOI: 10.1080/14737140.2023.2236793

Rebecca L Porter, Ursula A Matulonis

{"title":"Mirvetuximab soravtansine for platinum-resistant epithelial ovarian cancer.","authors":"Rebecca L Porter, Ursula A Matulonis","doi":"10.1080/14737140.2023.2236793","DOIUrl":"10.1080/14737140.2023.2236793","url":null,"abstract":"ABSTRACT Introduction Mirvetuximab soravtansine (mirvetuximab) is an antibody drug conjugate (ADC) comprised of a humanized folate receptor alpha (FRα)-binding monoclonal antibody attached via a cleavable linker to the cytotoxic maytansinoid molecule, DM4. FRα is expressed in several epithelial cancers, including high grade serous ovarian cancer (HGSOC). Mirvetuximab received accelerated approval by the United States Food and Drug Administration (FDA) in November 2022 based on the results of the SORAYA trial, which tested mirvetuximab for the treatment of patients with recurrent platinum resistant HGSOC with high FRα expression and showed an overall response rate (ORR) of 32.4% and a median duration of response of 6.9 months. Mirvetuximab toxicities included low grade ocular and gastrointestinal toxicities. The National Comprehensive Cancer Network (NCCN) ovarian cancer 2023 guidelines adopted mirvetuximab as 2A, and mirvetuximab combined with bevacizumab as 2B, recommendations. Areas covered This manuscript will review the preclinical and clinical development of mirvetuximab, the toxicities associated with mirvetuximab and mitigation strategies, and future applications of mirvetuximab. Expert opinion Mirvetuximab represents the first biomarker-directed therapy with an indication specifically for the treatment of PROC. The efficacy and favorable safety profile support further development of mirvetuximab and mirvetuximab combinations in platinum sensitive and newly diagnosed ovarian cancer.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":"23 8","pages":"783-796"},"PeriodicalIF":3.3,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10027275","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

What's to come in PSMA therapies and diagnostics: A summary of clinical trials involving PSMA radioligand-based therapeutic and/or diagnostic approaches with active recruitment. PSMA治疗和诊断的进展：涉及基于PSMA放射性配体的主动招募治疗和/或诊断方法的临床试验总结。

IF 3.3 3区医学

Expert Review of Anticancer Therapy Pub Date : 2023-07-01 Epub Date: 2023-06-28 DOI: 10.1080/14737140.2023.2223987

Debra Ann Dawson, Michael Lock, David Laidley, Glenn Bauman

{"title":"What's to come in PSMA therapies and diagnostics: A summary of clinical trials involving PSMA radioligand-based therapeutic and/or diagnostic approaches with active recruitment.","authors":"Debra Ann Dawson, Michael Lock, David Laidley, Glenn Bauman","doi":"10.1080/14737140.2023.2223987","DOIUrl":"10.1080/14737140.2023.2223987","url":null,"abstract":"Introduction: Prostate-Specific Membrane Antigen (PSMA)-based diagnostics and therapeutics are proving highly valuable in identifying disease sites and providing targeted radioligand therapy (RLT) for disseminated disease in prostate cancer (PC). With successful integration of these tools in limited PC presentations, there is a real need and excitement for trials testing PSMA-based approaches more broadly.Areas covered: We review the ongoing trials registered on ClinicalTrials.gov which aim to evaluate PSMA-PET or PSMA-RLT applications. We outline clinical contexts which have significant ongoing study and therefore may see imminent change, as well as contexts which are lacking in study in the hopes of guiding future research.Expert opinion: Trials examining intensification strategies through targeted radiotherapy, combination systemic therapies, and RLTs have the potential to demonstrate improved clinical outcomes using PSMA-PET CT for guidance. We expect that PSMA-PET will become fundamental in the work-up of patients before targeted radiotherapy or surgery. The results of ongoing trials will likely clarify the benefits of PSMA-RLT in metastatic PC including in oligometastatic and hormone-sensitive disease; however, there is a sparsity of trials evaluating PSMA-RLT outside of metastatic PC. Clinical trials with PSMA PET/CT as an endpoint for disease control are emerging and standardized reporting and metrics for PSMA staging and response will facilitate the inclusion of PSMA PET endpoints into therapeutic trials.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":"23 8","pages":"835-851"},"PeriodicalIF":3.3,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10029394","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Emerging agents for the treatment of advanced or metastatic NSCLC without actionable genomic alterations with progression on first-line therapy. 新出现的治疗晚期或转移性NSCLC的药物，在一线治疗中没有可操作的基因组改变。

IF 3.3 3区医学

Expert Review of Anticancer Therapy Pub Date : 2023-07-01 Epub Date: 2023-07-24 DOI: 10.1080/14737140.2023.2235895

Ticiana Leal, Mark A Socinski

{"title":"Emerging agents for the treatment of advanced or metastatic NSCLC without actionable genomic alterations with progression on first-line therapy.","authors":"Ticiana Leal, Mark A Socinski","doi":"10.1080/14737140.2023.2235895","DOIUrl":"10.1080/14737140.2023.2235895","url":null,"abstract":"Introduction: Lung cancer is the second most common cancer in the world and the leading cause of cancer-related mortality. Immune checkpoint inhibitors (ICIs), as monotherapy or in combination with platinum-based chemotherapy, have emerged as the standard of care first-line treatment option for patients with advanced non-small cell lung cancer (NSCLC) without actionable genomic alterations (AGAs). Despite significant improvements in patient outcomes with these regimens, primary or acquired resistance is common and most patients develop disease progression, resulting in poor survival.Areas covered: We review the current treatments commonly used for NSCLC without AGAs in the first-line and subsequent settings and describe the unmet needs for these patients in the second-line setting, including a lack of standard definitions for primary and required resistance, and few effective treatment options for patients who develop progression of their disease on first-line therapy. We describe key mechanisms of resistance to ICIs and emerging therapies that are being investigated for patients who develop progression on ICIs and platinum-based chemotherapy.Expert opinion: Emerging agents in development have a variety of different mechanisms of action and will likely change standard of care for second-line therapy and beyond for patients with NSCLC without AGAs in the future.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":"23 8","pages":"817-833"},"PeriodicalIF":3.3,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10087785","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Management of Oncogene Driven Locally Advanced Unresectable Non-small Cell Lung Cancer. 肿瘤基因驱动的局部晚期不可切除非小细胞肺癌癌症的治疗。

IF 3.3 3区医学

Expert Review of Anticancer Therapy Pub Date : 2023-07-01 Epub Date: 2023-08-13 DOI: 10.1080/14737140.2023.2245140

Jerold Loh, Jia Li Low, Manavi Sachdeva, Peter Qj Low, Rachel Su Jen Wong, Yiqing Huang, Puey Ling Chia, Ross A Soo

引用次数: 0